News and Trends 26 Aug 2015
Ouch! Novo Nordisk fails in Phase III
Novo Nordisk joins UCB and gets knocked down by its drug’s final clinical trial. Liraglutide, the already approved adjunct therapy for people with type 2 diabetes won’t reach out to type 1 diabetes. Novo Nordisk can look at a 90-year long history of improving the lives of diabetes patients. However, the phase IIIa trial that […]